Obtenga las últimas noticias sobre las acciones de Kairos Pharma con actualizaciones sobre las tendencias del mercado, las finanzas y el análisis de Benzinga. Manténgase informado sobre el rendimiento de KAPA

Últimas noticias sobre

KAIROS PHARMA LTD

Kairos Pharma

Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. It is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma.

Section,Of,A,Financial,Newspaper,Titled,Key,Movers

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ADAP

AGMH

AIIO

ASST

ATCH

ATMV

CEVA

FTHM

KAPA

LASE

MGIH

RNAZ

RVPH

SCHL

SOWG

VTEX

XXII

Las acciones de FedEx (FDX) suben un 5%; Aquí están 20 acciones que se mueven en el pre-market de EE.UU.

Kairos Pharma Ltd

KAPA GOLD INC by KAPA GOLD INC.

Press Releases

Kairos Pharma, Ltd. Announces Data to be Presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

Kairos Pharma Ltd. Announces New Data on Small Molecule GITR Ligand Agonist KROS 101 as Promising Cancer Immunotherapy at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

Kairos Pharma Announces Positive Safety Results from Phase 2 Trial of ENV-105 in Advanced Prostate Cancer

Tech Momentum Surges as IPA, HIT, SNYR, PNPN.V, KAPA and Others Drive Investor Awareness – More Stocks Inside

Kairos Pharma Announces Participation and Presentation in the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025

Kairos Pharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Kairos Pharma Announces Presentation of New Phase 1 Data on ENV105 Combination Therapy in Non-Small Cell Lung Cancer at the World Lung Cancer Conference September 6-9, 2025

Kairos Pharma Announces Virtual KOL Event to Provide Perspectives on ENV105 Interim Efficacy Results in Advanced Prostate Cancer

Kairos Pharma Announces Positive Interim Efficacy Analysis of Phase 2 Trial of ENV105 in Advanced Prostate Cancer with Median Progression Free Survival of Over One Year

Kairos Pharma to Present Positive Safety and Efficacy Data from Phase 2 Prostate Cancer Trial at ESMO 2025

AMZN

COST

PLRZ

PNPNF

SNYR

TSXV:PNPN

Akari Therapeutics Plc - American Depositary Shares

Akari Therapeutics

Allarity Therapeutics, Inc. - Common stock

Allarity Therapeutics

Apimeds Pharmaceuticals US, Inc. Common Stock

Apimeds Pharmaceuticals

Aptevo Therapeutics

Boundless Bio

CASI Pharmaceuticals, Inc. - Ordinary Shares

CASI Pharmaceuticals

CollPlant Biotechnologies Ltd. - Ordinary Shares

CollPlant Biotechnologies

Enlivex Therapeutics Ltd. - Ordinary Shares

Enlivex Therapeutics

Fortress Biotech, Inc. - 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

Fortress Biotech

CytoMed Therapeutics Limited - Ordinary Shares

CytoMed Therapeutics

Kezar Life Sciences

Lunai Bioworks

Moleculin Biotech

MetaVia

Neuphoria Therapeutics Inc. - Common Stock

Neuphoria Therapeutics

Nanoviricides

NeuroSense Therapeutics Ltd. - Ordinary Shares

NeuroSense Therapeutics

Passage Bio

ProMIS Neurosciences Inc. - Common Shares

ProMIS Neurosciences

Propanc Biopharma

Rallybio

Rein Therapeutics

SAB Biotherapeutics

Sonnet BioTherapeutics Holdings, Inc. - Common Stock

Sonnet BioTherapeutics

Tharimmune

D. Boral Capital

HC Wainwright & Co.

Maxim Group

EF Hutton

Comments

Kairos Pharma Noticias bursátiles

Noticias

Últimas noticias sobre

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL